Bone marrow disease with impaired blood cell maturation in dogs (Myelodysplastic syndromes, MDS)
- Occurrence: very rare
- Location of disease: General/Whole body
When to visit the vet?
Non-urgent see a veterinarian within 2–3 days
If the condition worsens / symptoms persist, consult a veterinarian.
Definition
Myelodysplastic syndromes (MDS) in dogs are a group of disorders characterized by abnormal development and maturation of hematopoietic stem cells in the bone marrow, leading to insufficient production of healthy blood cells.
Das Wichtigste auf einen Blick
Myelodysplastic syndromes (MDS) in dogs affect the stem cells in the bone marrow responsible for producing all types of blood cells. In MDS, this process is disrupted, leading to inefficient blood cell formation. The causes are diverse and can include genetic mutations or acquired factors such as environmental influences that damage the DNA of stem cells. The immune system can also play a role by impairing normal cell formation. Symptoms of MDS include weakness, pale mucous membranes, increased susceptibility to infection, and anemia. Diagnosis requires blood tests and often a bone marrow examination. Genetic tests can be used as a supplement. Treatment is complex and often includes blood transfusions as well as medications that stimulate blood cell formation. Immunosuppressive therapies may be required to control autoimmune reactions. The prognosis varies greatly and depends on the severity of the disease and the response to treatment. Preventive measures are difficult because the exact cause is often unclear. However, general health care can reduce the risk of complications. Research focuses on genetic mechanisms to develop better diagnostic and therapeutic methods. Advances in research could benefit not only dogs but also human medicine.
Ursachen
The hematopoietic stem cells in the bone marrow are responsible for producing all types of blood cells, including red blood cells, white blood cells, and platelets. In MDS, this process is disrupted, leading to inefficient hematopoiesis. The cause of this disorder is often complex and may include both genetic and acquired factors.
Genetic causes could be triggered by mutations in genes that control cell division and maturation. These mutations can occur spontaneously or be inherited. Acquired factors could include environmental influences such as toxins, certain medications, or radiation that damage the DNA of stem cells and lead to their dysfunctional maturation.
Another important aspect is the role of the immune system, which can sometimes affect the development of normal blood cells in the bone marrow. Autoimmune reactions can disrupt the formation of healthy blood cells, contributing to the symptoms of MDS. There is also evidence that chronic infections and inflammatory conditions can increase the risk of developing MDS.
Symptoms
Symptoms of MDS in dogs can vary depending on which type of blood cell is most severely affected. General symptoms include lethargy, weakness, and weight loss caused by anemia resulting from insufficient red blood cell production.
If white blood cell production is insufficient, the dog may be more susceptible to infection, which can manifest as frequent or severe infections. A reduced number of platelets can lead to an increased tendency to bleed, noticeable through spontaneous bleeding, bleeding gums, or nosebleeds.
Other symptoms may include pale mucous membranes, shortness of breath, or an increased heart rate. These symptoms are often an indication that the dog needs further examination to rule out MDS or other blood disorders.
Diagnose
The diagnosis of MDS in dogs requires a comprehensive clinical assessment, which usually begins with a complete medical history and a physical examination. Blood tests are crucial and typically include a complete blood count to detect anomalies in blood cell numbers.
A bone marrow examination is often required to definitively diagnose MDS. This includes a bone marrow aspiration or biopsy, where a sample of the bone marrow is taken and examined under a microscope to assess cell morphology and identify dysplastic changes.
Further diagnostic tests may include genetic testing to identify specific mutations associated with MDS. Imaging techniques such as ultrasound or X-ray can also be used to identify secondary complications or underlying diseases.
Therapie
Treatment of MDS in dogs is often complex and requires a multimodal approach. Symptomatic treatments such as blood transfusions may be necessary to treat anemia and improve the dog’s quality of life.
Medications that stimulate the bone marrow, such as hematopoietic growth factors, may be prescribed to promote the production of healthy blood cells. In some cases, immunosuppressive therapies may be necessary to control autoimmune reactions that contribute to the disease.
Since MDS is often associated with genetic mutations, targeted therapies may be considered that focus on specific molecular abnormalities. This is an area of active research and is constantly evolving.
Prognose und Nachsorge
The prognosis for dogs with MDS varies greatly and depends on the severity of the disease, the affected blood cell line, and the response to treatment. In many cases, MDS is a progressive disease that can worsen over time.
Some dogs can maintain a good quality of life over a longer period with appropriate treatment and care, while others may have a more aggressive disease that is harder to control. Regular veterinary monitoring and treatment adjustments are crucial to achieving the best possible outcomes.
Prävention
Since the exact cause of MDS is often unclear and genetic factors can play a role, prevention is difficult. However, general health care, including regular veterinary check-ups and a balanced diet, can help promote the dog’s overall well-being and reduce the risk of secondary complications.
Avoiding known risk factors such as exposure to toxic substances and unnecessary radiation, as well as controlling infections and inflammatory conditions, can also be helpful. The breeding of dogs with known genetic predispositions for MDS should be carefully monitored to minimize the risk of passing on genetic anomalies.
Ausblick auf aktuelle Forschung
Myelodysplastic syndromes (MDS) in dogs are a group of complex disorders associated with abnormal development and maturation of stem cells in the bone marrow. Research on MDS in dogs is still relatively limited, as this disease is diagnosed less frequently in them than in humans. Nevertheless, there are some advances in the study of this disease that may be significant for both veterinary medicine and human medicine.
Current studies focus on the genetic and molecular mechanisms leading to the development of MDS. Researchers are trying to identify specific genetic mutations and epigenetic changes that increase the risk of developing these disorders. These genetic investigations are crucial for better understanding how MDS develops in dogs and what parallels it shares with human diseases.
Another research focus is on improving diagnostic methods. Currently, a bone marrow biopsy is often performed to diagnose MDS—an invasive procedure. Researchers are working on developing less invasive diagnostic tests, such as blood tests targeting specific biomarkers. These could facilitate and speed up diagnosis in the future.
There are also advances in the treatment of MDS in dogs. Traditionally, MDS in dogs is treated with supportive therapy, such as blood transfusions and medications to stimulate hematopoiesis. Current research approaches are investigating the use of targeted therapies that directly address the genetic changes causing MDS. Stem cell therapy is also being studied as a potential treatment option, with a focus on bone marrow regeneration.
Research findings could not only improve the treatment and prognosis of dogs with MDS but also provide insights into the pathogenesis of similar diseases in humans. Since dogs share many genetic and physiological similarities with humans, findings from veterinary research could also be transferable to human medicine, potentially promoting the development of new therapeutic approaches.
Frequently Asked Questions (FAQs)
1. What are myelodysplastic syndromes in dogs?
2. What symptoms do dogs with MDS show?
3. How is MDS diagnosed in dogs?
4. What are the main causes of MDS in dogs?
5. Is there a cure for MDS in dogs?
6. Can all dog breeds develop MDS?
7. How long can a dog with MDS live?
8. What treatments are available for dogs with MDS?
9. Are there preventive measures to prevent MDS in dogs?
10. How does MDS in dogs differ from MDS in humans?
Literatur
- Meredith, A. M., Beeler-Marfisi, J., Berke, O., Mutsaers, A. J., & Bienzle, D. (2025). Standardized bone marrow assessment, risk variables, and survival in dogs with myelodysplastic syndrome and acute myeloid leukemia. Veterinary Pathology, 62(1), 64–73. https://doi.org/10.1177/03009858241277982
- Weiss, D. J., & Smith, S. A. (2000). Primary myelodysplastic syndromes of dogs: A report of 12 cases. Journal of Veterinary Internal Medicine, 14(5), 491–494.
- Weiss, D. J., & Aird, B. (2001). Cytologic evaluation of primary and secondary myelodysplastic syndromes in the dog. Veterinary Clinical Pathology, 30(2), 67–75. https://doi.org/10.1111/j.1939-165X.2001.tb00261.x
- Weiss, D. J. (2003). New insights into the physiology and treatment of acquired myelodysplastic syndromes and aplastic pancytopenia. Veterinary Clinics of North America: Small Animal Practice, 33(6), 1317–1334. https://doi.org/10.1016/S0195-5616(03)00094-9
- Weiss, D. J. (2005). Recognition and classification of dysmyelopoiesis in the dog: A review. Journal of Veterinary Internal Medicine, 19(2), 147–154.
- Juopperi, T. A., Bienzle, D., Bernreuter, D. C., Vernau, W., Thrall, M. A., McManus, P. M., Lappin, M. R., & Teske, E. (2011). Prognostic markers for myeloid neoplasms: A comparative review. Veterinary Pathology, 48(1), 182–191. https://doi.org/10.1177/0300985810389317